Traitement des cancers de l'enfant en Afrique : résultats préliminaires du groupe francoafricain d'oncologie pédiatrique-Reference-Cited by-同舟云学术

Traitement des cancers de l'enfant en Afrique : résultats préliminaires du groupe francoafricain d'oncologie pédiatrique

Published:2005-06 Issue:6 Volume:12 Page:851-853
ISSN:0929-693X
Container-title:Archives de Pédiatrie
language:fr
Short-container-title:Archives de Pédiatrie

Author:

Harif M.,Barsaoui S.,Benchekroun S.,Boccon-Gibod L.,Bouhas R.,Doumbé P.,El Haffaf Z.,Khattab M.,Ladjadj Y.,Mallon B.,Moreira C.,Msefer-Alaoui F.,Patte C.,Rakotonirina G.,Raphael M.,Raquin M.A.,Tournade M.F.,Lemerle J.

Publisher

Elsevier BV

Subject

Pediatrics, Perinatology and Child Health

Reference3 articles.

1. Peut-on traiter les cancers des enfants en Afrique ? L'action du groupe francoafricain d'oncologie pédiatrique;Lemerle;MT Pediatr.,2003

2. Optimal duration of preoperative therapy in unilateral and non-metastatic Wilms' tumor in children older than 6 months: results of the ninth international society of pediatric oncology Wilms tumor trial and study;Tournade;J. Clin. Oncol.,2001

3. The Société française d'oncologie pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphoma and L3 leukemia;Patte;Blood,2001

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surgical aspects and outcomes after nephrectomy for Wilms tumour in sub‐Saharan Africa: A report from Wilms Africa Phase II—CANCaRe Africa;Pediatric Blood & Cancer;2024-06-19

2. Survival Outcome of Wilms Tumor with Multi-Modality Treatment at Jimma Hospital, Southwest Ethiopia;Open Journal of Urology;2023

3. Post-Therapy Surveillance of Wilms’ Tumor Survivors;Wilms’ Tumor;2022

4. Wilms tumor in Africa: A systematic review of management challenges and outcome in two decades (2000‐2019);Pediatric Blood & Cancer;2020-09-10

5. Sustainable care for children with cancer: a Lancet Oncology Commission;The Lancet Oncology;2020-04